<scp>GAD65</scp> Antibody <scp>ELISA</scp> With Extended Reportable Range: Validation and Guidance for Neurological Practice
GAD65 ELISA and RIA have equivalent sensitivity for autoimmune diabetes and neurological testing, with higher specificity for ELISA. A serum cut-off of 10,000 IU/mL is informative but requires clinical context, and dilution of screen > 250 IU/mL samples is essential for neurological interpretation.
Authors
- Anastasia Zekeridou
- Maria Alice V. Willrich (ORCID: https://orcid.org/0000-0002-9318-7091)
- Sarosh R. Irani (ORCID: https://orcid.org/0000-0002-7667-9748)
- Daniel H. Lachance (ORCID: https://orcid.org/0000-0002-5475-9931)
- Andrew B. McKeon (ORCID: https://orcid.org/0000-0001-6856-8143)
- Dana Olofson
- Diana Anissian
- John R. Mills (ORCID: https://orcid.org/0000-0003-1025-4760)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Max C. Herman
- Divyanshu Dubey
- Eoin P. Flanagan
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2026-03-28
- DOI
- https://doi.org/10.1002/acn3.70378
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00